著者

高橋 佐江子 笹代 純平 清水 怜有 鈴木 章 高嶋 直美 堀田 泰史 久々知 修平 深見 和矢 中嶋 耕平 奥脇 透

出版者

独立行政法人 日本スポーツ振興センター国立スポーツ科学センター

雑誌

Journal of High Performance Sport (ISSN:24347299)

巻号頁・発行日

vol.10, pp.11-23, 2022 (Released:2022-05-22)

参考文献数

24

---

In order to investigate the effect of sports activities restriction during the COVID-19 pandemic on physical function among athletes, this study compared the physical measurements of athletes from immediately after lifting the restriction of activities with their measurements after returning to competition. The subjects were twenty-nine Japanese top-level athletes (male: 14, female: 15). Measurements of the upper limbs, trunk, and lower limbs were performed from the viewpoint of injury prevention. The results showed that in female athletes, the upper limb functions of external rotation at maximum elevation and scapular adduction, and lower limb muscle power and muscle mass were significantly improved after returning to competition compared to immediately after the lifting of restrictions. There was no significant difference observed in the trunk measurements of both male and female athletes. In the future, these results will be useful in conditioning athletes if sports activities are once again restricted.

著者

小笠原 定久 池田 公史 山下 竜也 工藤 正俊 稲葉 吉隆 森本 学 土谷 薫 清水 怜 小島 康志 平岡 淳 能祖 一裕 相方 浩 沼田 和司 佐藤 俊哉 奥坂 拓志 古瀬 純司

雑誌

第19回日本臨床腫瘍学会学術集会

巻号頁・発行日

2022-02-04

著者

高山 クミ 清水 怜奈 加藤 安菜

出版者

亜細亜大学経営学部

雑誌

ホスピタリティ・マネジメント (ISSN:21850402)

巻号頁・発行日

vol.6, no.1, pp.179-238, 2015

著者

小林 美沙樹 小田中 みのり 鈴木 真也 船崎 秀樹 高橋 秀明 大野 泉 清水 怜 光永 修一 池田 公史 市田 泰彦 高橋 邦雄 齊藤 真一郎

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.41, no.1, pp.18-23, 2015-01-10 (Released:2016-01-15)

参考文献数

9

被引用文献数

1 2

---

Hand-foot skin reaction (HFSR) is one of the major adverse effects of sorafenib necessitating discontinuation of the drug, however, no standard interventions for HFSR have been established yet. At our hospital, we are using a urea-containing cream prophylactically for HFSR associated with sorafenib. We carried out this study in 74 hepatocellular carcinoma patients receiving treatment with sorafenib at our hospital between June 2009 and January 2011 to assess the benefit of prophylactic use of urea-containing cream against sorafenib-induced HFSR. Patients with a history of previous use of tyrosine kinase inhibitors or insufficient data in respect of the dose of urea-containing cream were excluded. The patients were divided into a high-dose group (38 patients) and a low-dose group (36 patients) according to the median dose (2.9 g per day) of urea-containing cream used within the first 2 weeks after the start of sorafenib treatment. The frequency of grade 2 or 3 HFSR was 42.1% in the high-dose group and 61.1% in the low-dose group(P = 0.105). The relative dose intensity of sorafenib was 71.1% in the high-dose group and 59.6% in the low-dose group (P = 0.043). No significant difference was observed in the response rate or time to progression between the two groups. In conclusion, prophylactic use of a urea-containing cream might enhance the relative dose intensity of sorafenib, but further prospective studies are warranted to elucidate its usefulness.